Louisiana State University Schools of Medicine (LSU) in New Orleans and in Shreveport (LSU-NO and LSU-S) are applying for grant support to participate in the clinical trials and scientific research programs of the Southwest Oncology Group. LSU-NO has been a Group member since 1965 with LSU-S joining as a co-member in 1982. Although currently not funded, LSU has continued as an active Group member, enrolling a record number of patients. From October 1, 1990, to September 30, 1991, (period reported in the continuing application of the Group) LSU registered 167 patients compared to 73 in the same period in 1987-88. This 129 percent increase in accrual has been possible by an institutional commitment to improve the care of the indigent and minority patients who make up almost all the patients seen at our centers and by participation in the UCOP, High Priority, and CTEP Minority Initiative Programs. LSU has recruited a record number of Group members from all cancer care specialties emphasizing a multimodality approach to cancer care. By concentrating our resources, we have become one of the top UCOP programs in the country with 55 enrollments this period and one of the leading registrants to both the CTEP Minority Initiatives and the High Priority Programs. Quality data has been consistently submitted with our quality ranking being above average. With full grant funding we plan to: 1) expand availability of clinical trials to indigent and minority patients in other areas of the state by opening satellites at four regional hospitals supervised by LSU-S or LSU-NO, 2) enhance CGOP accrual by providing full data management support, and 3) and continue accruing a high number of patients while maintaining the quality of data. LSU has overcome past criticisms of limited patient accrual and shown the capability of being a major Group participant.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA058658-05
Application #
2008175
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-04-01
Project End
1997-12-31
Budget Start
1997-01-01
Budget End
1997-12-31
Support Year
5
Fiscal Year
1997
Total Cost
Indirect Cost
Name
Louisiana State University Hsc Shreveport
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Shreveport
State
LA
Country
United States
Zip Code
71103
Wozniak, Antoinette J; Moon, James; Thomas Jr, Charles R et al. (2015) A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer 16:340-7
Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Stiff, Patrick J; Unger, Joseph M; Cook, James R et al. (2013) Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med 369:1681-90
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Petersdorf, Stephen H; Kopecky, Kenneth J; Slovak, Marilyn et al. (2013) A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia. Blood 121:4854-60
Berglund, Ryan K; Tangen, Catherine M; Powell, Isaac J et al. (2012) Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. Urology 79:633-7

Showing the most recent 10 out of 92 publications